File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Role of cytoreductive nephrectomy (CRN) for metastatic renal cell carcinoma (mRCC) in the era of targeted therapy (TKI): experience from three hong kong tertiary centres

TitleRole of cytoreductive nephrectomy (CRN) for metastatic renal cell carcinoma (mRCC) in the era of targeted therapy (TKI): experience from three hong kong tertiary centres
Authors
Issue Date2014
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
Hong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 2 How to Cite?
AbstractObjective: Investigate the practice of CRN and TKI in treatment of mRCC in three tertiary centres in Hong Kong. Patients & Methods: Metastatic RCC patients with either CRN or TKI from 2006 to 2013 in three tertiary centres were studied. Primary endpoint is the overall survival (OS) while secondary endpoint is the time to progression. All CRN group was compared with TKI group and subgroup analysis of CRN + TKI (post CRN target given) versus TKI was performed as well. Results: A total of 73 patients were reviewed, with 41 (56%) in CRN group while 32 (44%) in TKI group. For the CRN (with or without subsequent TKI) group versus TKI only, 48.8% patients survived versus 12.5% respectively (p  =  0.01) while 77.5% patients progressed versus 78.1% respectively (p = 0.89). For the CRN group, 22 patients (53.7%) received immediate target therapy while 19 patients (46.3%) did not. For the post nephrectomy pathology 89.3% (25 patients) yielded clear cell RCC and with 11.1% T1, 29.6% T2, 55.6% T3, and 3.7% T4 tumours. The most commonly used TKI agents were sunitinib (76.9%) followed by sorafenib (11.5%) and pazopanib (7.7%). Conclusion: Our study reflects the current practice of treatment for metastatic RCC in the era of targeted therapy.
DescriptionOral Presentation
Persistent Identifierhttp://hdl.handle.net/10722/193956
ISSN
2015 Impact Factor: 4.387
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorChan, KWen_US
dc.contributor.authorTsu, HLJen_US
dc.contributor.authorMa, WKen_US
dc.contributor.authorKan, CFen_US
dc.contributor.authorLeung, AKCen_US
dc.contributor.authorIp, CHen_US
dc.contributor.authorKan, WMen_US
dc.contributor.authorCheung, FKen_US
dc.contributor.authorChan, WHen_US
dc.contributor.authorAu, WHen_US
dc.contributor.authorYiu, MKen_US
dc.date.accessioned2014-01-28T06:38:21Z-
dc.date.available2014-01-28T06:38:21Z-
dc.date.issued2014en_US
dc.identifier.citationHong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 2en_US
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/193956-
dc.descriptionOral Presentation-
dc.description.abstractObjective: Investigate the practice of CRN and TKI in treatment of mRCC in three tertiary centres in Hong Kong. Patients & Methods: Metastatic RCC patients with either CRN or TKI from 2006 to 2013 in three tertiary centres were studied. Primary endpoint is the overall survival (OS) while secondary endpoint is the time to progression. All CRN group was compared with TKI group and subgroup analysis of CRN + TKI (post CRN target given) versus TKI was performed as well. Results: A total of 73 patients were reviewed, with 41 (56%) in CRN group while 32 (44%) in TKI group. For the CRN (with or without subsequent TKI) group versus TKI only, 48.8% patients survived versus 12.5% respectively (p  =  0.01) while 77.5% patients progressed versus 78.1% respectively (p = 0.89). For the CRN group, 22 patients (53.7%) received immediate target therapy while 19 patients (46.3%) did not. For the post nephrectomy pathology 89.3% (25 patients) yielded clear cell RCC and with 11.1% T1, 29.6% T2, 55.6% T3, and 3.7% T4 tumours. The most commonly used TKI agents were sunitinib (76.9%) followed by sorafenib (11.5%) and pazopanib (7.7%). Conclusion: Our study reflects the current practice of treatment for metastatic RCC in the era of targeted therapy.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU Internationalen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.titleRole of cytoreductive nephrectomy (CRN) for metastatic renal cell carcinoma (mRCC) in the era of targeted therapy (TKI): experience from three hong kong tertiary centresen_US
dc.typeConference_Paperen_US
dc.identifier.emailTsu, HLJ: jamestsu@hku.hken_US
dc.identifier.emailYiu, MK: pmkyiu@hku.hken_US
dc.identifier.doi10.1111/bju.12606-
dc.identifier.hkuros227495en_US
dc.identifier.hkuros228434-
dc.identifier.volume113-
dc.identifier.issueSuppl. S1-
dc.identifier.spage2-
dc.identifier.epage2-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats